RBMNF yields 12820.51% · PFE yields 6.13%● Live data
📍 RBMNF pulled ahead of the other in Year 1
Combined, RBMNF + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of RBMNF + PFE for your $10,000?
Rugby Resources Ltd., an exploration stage company, engages in the acquisition, exploration, and development of mineral properties in Colombia, Argentina, Chile, Australia, and the Philippines. It primarily explores for gold, silver, and copper deposits. The company holds an interest in the Motherlode gold-copper project that covers an area of 878 hectares located to the south of Surigao City in Surigao del Norte province, the Philippines; 100% interest the Colombia gold project covering an area of approximately 287 square kilometers; 100% interest in the Cobrasco copper project that covers approximately 3,000 hectares located in the Choco Region of Colombia; and Georgetown project comprising three exploration permits totaling 849 square kilometers located in North Queensland, Australia. It also holds an option to earn up to 100% interest in the El Zanjon gold and silver project covering approximately 600 square kilometers located in Santa Cruz Province, Argentina, as well as has an option agreement to acquire the Tantalus gold silver project situated in the Bucaramanga gold belt, Colombia; and Salvadora Silver-Copper-Gold Project comprising 35 individual exploration and mining concessions covering an aggregate area of 6,924 hectares. The company was formerly known as Rugby Mining Limited and changed its name to Rugby Resources Ltd. in August 2022. Rugby Resources Ltd. was incorporated in 2007 and is headquartered in Vancouver, Canada.
Full RBMNF Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.